Iheezo is a physician-administered gel that allows for localized anesthesia administration; it is the first branded ocular anesthetic approved by the FDA in 14 years.
Iheezo demonstrated safety and efficacy in three clinical trials, where it numbed the eye surface in one to one and a half minutes, and maintained numbness for 22 minutes without any supplemental treatment.
“We have always believed in the unique clinical value of Iheezo, and now that Iheezo is approved for use in the U.S. market, it has the potential to become an indispensable premium tool for eyecare professionals and their patients requiring ocular surface anesthesia,” Mark Baum, Harrow’s CEO, said in a Sept. 27 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.